A multi-cohort validated OXPHOS signature predicts survival and immune profiles in grade II/III glioma patients

A multi-cohort validated OXPHOS signature predicts survival and immune profiles in grade II/III glioma patients

IntroductionGrade II/III gliomas are invasive brain tumors with a high risk of malignant progression and significant clinical heterogeneity, highlighting the urgent need for reliable prognostic biomarkers to guide personalized treatment strategies. This study aimed to investigate the molecular mecha...

Full description

Saved in:

Bibliographic Details
Main Authors:	Jun Mou, Min Zhang, Fumin Qin, Yajie Cui, Keyou Xu, Baoye Pang, Xinyue Li, Wanyi Tan, Aiqi Yang, Yaxin Liu, Lingjun Shen, Yanting Liu, Kai Xu
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-08-01
Series:	Frontiers in Immunology
Subjects:	grade II/III gliomas mitochondrial oxidative phosphorylation prognostic gene signature RiskScore model immune microenvironment
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2025.1638824/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

A novel 5-protein kinase risk signature for predicting glioma prognosis and immunotherapy responsiveness
by: Senbin Wu, et al.
Published: (2025-07-01)

Interrogation of macrophage-related prognostic signatures reveals a potential immune-mediated therapy strategy by histone deacetylase inhibition in glioma
by: Xisen Wang, et al.
Published: (2025-06-01)

Dabrafenib plus trametinib in low-grade versus high-grade gliomas: a systematic review and meta-analysis
by: Bardia Hajikarimloo, et al.
Published: (2024-11-01)

Multi-omics analysis identifies SNP-associated immune-related signatures by integrating Mendelian randomization and machine learning in hepatocellular carcinoma
by: Qingyan Kou, et al.
Published: (2025-07-01)

Comprehensive analysis reveals cholesterol metabolism-related signature for predicting prognosis and guiding individualized treatment of glioma
by: Dengfeng Lu, et al.
Published: (2025-01-01)

Development of a reliable risk prognostic model for lung adenocarcinoma based on the genes related to endotheliocyte senescence
by: Hongzhi Li, et al.
Published: (2025-04-01)

Expression of toll-like receptors and inflammatory mediators in primary human glioma cells (low- and high-grade) compared to primary cells from epileptic human brain
by: Negin Masoomabadi, et al.
Published: (2025-09-01)

PEDIATRIC OPTIC PATHWAY GLIOMA: DIENCEPHALIC SYNDROME
by: A. F. Valiakhmetova, et al.
Published: (2021-03-01)

The Multi-Voxel MRS of Glioma: Glycine is a Suitable Biomarker for Tumor Grading
by: Hossein Taheri, et al.
Published: (2025-07-01)

Breed-Associated Differences in Differential Gene Expression Following Immunotherapy-Based Treatment of Canine High-Grade Glioma
by: Susan A. Arnold, et al.
Published: (2024-12-01)

Magnetic Resonance Imaging Radiomics-Driven Artificial Neural Network Model for Advanced Glioma Grading Assessment
by: Yan Qin, et al.
Published: (2025-06-01)

Transcriptomic HEPN1 signatures predict treatment response in low grade glioma
by: Lei Jiao, et al.
Published: (2025-08-01)

Study Protocol of a Prospective Phase 2 Study of Chlorophyllin for the Management of Brain Radionecrosis in Patients With Diffuse Glioma (CHROME)
by: Archya Dasgupta, et al.
Published: (2025-03-01)

Morphometric and radiomics analysis toward the prediction of epilepsy associated with supratentorial low-grade glioma in children
by: Min-Lan Tsai, et al.
Published: (2025-05-01)

Cinnamaldehyde impacts key cellular signaling pathways for induction of programmed cell death in high-grade and low-grade human glioma cells
by: Yoo Na Kim, et al.
Published: (2025-01-01)

European standard clinical practice recommendations for paediatric high-grade gliomas
by: Elwira Szychot, et al.
Published: (2025-06-01)

Novel metabolic subtypes in IDH-mutant gliomas: implications for prognosis and therapy
by: Peng Wang, et al.
Published: (2025-04-01)

LARS2 DNA methylation predicts the prognosis in colon cancer
by: Yingzhou Fu, et al.
Published: (2025-07-01)

Ras-AKT signaling represses the phosphorylation of histone H1.5 at threonine 10 via GSK3 to promote the progression of glioma
by: Ben Sang, et al.
Published: (2019-12-01)

Multidisciplinary treatment of pediatric low-grade glioma: Experience of children cancer hospital of Egypt; 2007-2012
by: Mohamed Ahmed Fawzy, et al.
Published: (2018-01-01)

Vorasidenib- A Paradigm Shift in IDH1- or IDH2-Mutant Low-Grade Glioma Treatment
by: Hurais Malik, et al.
Published: (2024-09-01)

Integrated genomic analysis of the stemness index signature of mRNA expression predicts lung adenocarcinoma prognosis and immune landscape
by: Xingzhao Lu, et al.
Published: (2025-02-01)

Construction and clinical application of a risk model based on N6-methyladenosine regulators for colorectal cancer
by: Hanhan Zhu, et al.
Published: (2024-12-01)

Complexities in Pediatric Oncology: A Case of Misdiagnosed High‐Grade Glioma Transforming Into Fibrosarcoma
by: Bijita Aryal, et al.
Published: (2025-07-01)

OXPHOS inhibition overcomes chemoresistance in triple negative breast cancer
by: Cemile Uslu, et al.
Published: (2025-06-01)

Immunology and prospects of immunotherapy against malignant gliomas: humoral immunity
by: S. A. Kulyova, et al.
Published: (2021-12-01)

DSN1 may predict poor prognosis of lower-grade glioma patients and be a potential target for immunotherapy
by: Yulong Jia, et al.
Published: (2024-12-01)

Awake Craniotomy for Left Insular Low-Grade Glioma Removal on a Patient with Learning Disabilities
by: Andrej Vranic, et al.
Published: (2017-02-01)

A gene signature related to programmed cell death to predict immunotherapy response and prognosis in colon adenocarcinoma
by: Lei Zheng, et al.
Published: (2025-02-01)

Clinical significance and immune infiltration analyses of the coagulation factor V gene in brain lower grade glioma
by: Yu Wang, et al.
Published: (2025-04-01)

Predictive role of MGMT and IDH status in the efficacy of bevacizumab for high-grade glioma: a retrospective study
by: Bai Xuexue, et al.
Published: (2025-08-01)

Curative timed NK cell-based immunochemotherapy aborts brain tumour recurrence driven by mesenchymal glioma stem cells
by: Brian Meehan, et al.
Published: (2025-03-01)

Deep learning and pathomics analyses predict prognosis of high-grade gliomas
by: Yuchen Zhu, et al.
Published: (2025-08-01)

The prognostic significance of the NMD core factor UPF1 in low-grade glioma
by: Shuo Yang, et al.
Published: (2025-07-01)

Expression and prognostic value of ferritinophagy-related NCOA4 gene in low-grade glioma: integration of bioinformatics and experimental validation
by: Guangtang Chen, et al.
Published: (2025-01-01)

Differentiation therapy targeting the stalled epigenetic developmental programs in pediatric high-grade gliomas
by: Wang Xiang, et al.
Published: (2025-02-01)

Deep learning-driven modality imputation and subregion segmentation to enhance high-grade glioma grading
by: Jiabin Yu, et al.
Published: (2025-05-01)

Efficacy and safety of low-dose X-rays based intraoperative radiotherapy for high-grade gliomas: a single-center retrospective study
by: Zhongcheng Wen, et al.
Published: (2025-05-01)

An exceptionally rare case of a diffuse midline glioma with concomitant H3.1 K27M and G34R mutations in the HIST1H3C (H3C3) gene
by: Zita Reisz, et al.
Published: (2025-01-01)

Reverse swing‐M, phase 1 study of repurposing mebendazole in recurrent high‐grade glioma
by: Vijay M. Patil, et al.
Published: (2020-07-01)